Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03612154
Other study ID # NCC-2018-0232
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 2, 2019
Est. completion date December 31, 2023

Study information

Verified date April 2022
Source National Cancer Center, Korea
Contact Ji-Youn Han, MD.Ph.D.
Phone 82-31-920-1154
Email jymama@ncc.re.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.


Description:

ROS1 rearrangement characterizes a small subset (1-2%) of non-small cell lung cancer (NSCLC) and is associated with light or never smoking patients and adenocarcinoma histology. Recently, ROS1 inhibitors such as crizotinib and ceritinib demonstrated significant efficacy in ROS1 rearranged NSCLC. Thus, identification of ROS1 rearrangement in NSCLC is mandatory to permit ROS1 targeted therapy. However, current guidelines either do not refer to ROS1 testing or mention it briefly without making any strong recommendation. The detection of ROS1rearrangement is based on in situ (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH]) and extractive non-in situ assays. While FISH still represents the gold standard in clinical trials, this technique may fail to recognize rearrangements of ROS1 with some gene fusion partner. On the other hand, IHC is the most cost-effective screening technique, but it seems to be characterized by low specificity. Extractive molecular assays are expensive and laborious methods, but they specifically recognize almost all ROS1 fusions using a limited amount of mRNA even from formalin-fixed, paraffin-embedded tumor tissues. Recently, Korean Heath Insurance Review and Assessment Service (HIRA) approved next generation sequencing (NGS)-based target sequencing for NSCLC patients, which may facilitate the detection of ROS1 rearrangement in Korean patients with advanced NSCLC. Lorlatinib is a new, potent, brain-penetrant, ATP-competitive small molecule inhibiter of ALK/ROS1. However, the objective response rate (ORR) was 17/47 (36.2%; 95% CI 22.7, 51.5) in ROS1 arm of B7461001 study, but this result may not represent the ORR of lorlatinib as a 1st line treatment since 53% had central nervous system involvement at baseline and 72% of patients had received prior crizotinib. Therefore, given the activity of lorlatinib in ROS1 rearranged lung cancer, The investigator will investigate the efficacy of lorlatinib in ROS1 inhibitor-naïve patients with ROS1- rearranged NSCLC. The investigator will also investigate the efficacy according to fusion partners and resistance mechanisms. Finally, The investigator will compare the concordance among diagnostic tests including FISH, IHC and NGS-based target sequencing and provide the clinical guidance for diagnosis of ROS1 rearrangement in NSCLC.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility 4.1. Inclusion criteria 1. Metastatic or recurrent NSCLC with ROS1 rearrangement identified by NGS-based target sequencing 2. Treatment naïve or one prior systemic treatment with platinum doublet chemotherapy 3. At least one measurable disease lesion according to RECIST 1.1 4. ECOG performance status 0-2 5. Age = 18 years 6. Adequate hematologic, hepatic, and renal function 7. Written informed consent 4.2. Exclusion criteria 1. Life expectancy of less than 12 weeks 2. Prior treatment with a ROS1 inhibitor 3. Symptomatic uncontrolled brain metastasis 4. Other malignancy within 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent 5. Uncontrolled intercurrent illness 6. Pregnancy or unwillingness to use effective birth control 7. Known hypersensitivity to lorlatinib and/or its excipients

Study Design


Intervention

Drug:
Lorlatinib
Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.

Locations

Country Name City State
Korea, Republic of National Cancer Center Goyang-Si Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Center, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR To assess the clinical efficacy of lorlatinib as measured by ORR using RECIST criteria v 1.1 from Cycle1 Day 1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months").
See also
  Status Clinical Trial Phase
Recruiting NCT06147570 - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01312337 - Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT05860582 - A Study of [14C]GB491 in Male Healthy Subjects Phase 1
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT02562027 - SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer N/A
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Active, not recruiting NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Terminated NCT03998189 - Metabolic and Microbial Profiling of Lung Cancer N/A
Not yet recruiting NCT03258671 - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer N/A
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Active, not recruiting NCT04984811 - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Phase 2
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Recruiting NCT02974933 - Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Phase 2
Recruiting NCT02951611 - Effects of Acupuncture Stimulation on Systemic Inflammation N/A
Active, not recruiting NCT02980536 - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Completed NCT02972216 - Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Phase 4
Recruiting NCT02905591 - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Phase 2
Recruiting NCT05873439 - Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC Early Phase 1
Active, not recruiting NCT02981108 - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Phase 1/Phase 2
Active, not recruiting NCT02299141 - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Phase 2